Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
67 mM) DMSO : 33
Smiles: CC1CC[C@@H]2[C@H](OC(=O)C2=C)[C@H]2O[C@]2(C)CCC=1 |c:19|
SCHEMBL282003
PubMed PMID: 15658359
GSK256066 is a potent and selective PDE4 inhibitor that can be given by inhalation
(-)-Cevimeline hydrochloride Catalog No.:M8813-2 67 mM) DMSO : 33( ) Cevimeline hydrochloride hemihydrate (( ) SNI 2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other tissues were investigated in mice, rats, guinea pigs, rabbits, and dogs. The in vitro metab. of SNI 2011 was also evaluated with rat and dog liver
US$ 64.95
US$ 118.00
US$ 139.95
US$ 65.00
US$ 38.00
US$ 145.00
US$ 65.00